argenx NV ADR (ARGX : NASDAQ)
Common Stock
$912.87
USD
-6.34 (-0.69%)
Last updated: 2026-10-05
Follow ARGX
ARGX
argenx NV ADR
WealthAwesomePerformance
1 Day
-0.69%
1 Week
-6.11%
1 Month
-11.64%
YTD
+8.68%
Key Statistics
Market Cap
$57.16B
52W High
$1072.75
52W Low
$661.85
P/E Ratio
34.96
50 Day MA
$956.72
200 Day MA
$851.23
Beta
-0.03
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/5/2026 | $920.83 | $923.31 | $903.50 | $912.87 | $912.87 | 322,128 |
| 10/2/2026 | $926.86 | $928.96 | $912.96 | $919.21 | $919.21 | 333,900 |
| 10/1/2026 | $957.22 | $972.38 | $935.24 | $936.00 | $936.00 | 302,200 |
| 9/30/2026 | $970.08 | $970.27 | $952.27 | $958.91 | $958.91 | 243,700 |
| 9/29/2026 | $965.05 | $974.25 | $956.25 | $970.66 | $970.66 | 311,000 |
| 9/28/2026 | $954.76 | $977.01 | $954.76 | $972.25 | $972.25 | 264,700 |
| 9/25/2026 | $965.23 | $967.71 | $956.24 | $959.49 | $959.49 | 264,400 |
| 9/24/2026 | $945.81 | $965.34 | $944.21 | $962.22 | $962.22 | 323,700 |
| 9/23/2026 | $974.60 | $974.60 | $934.18 | $945.82 | $945.82 | 426,500 |
| 9/22/2026 | $986.43 | $986.77 | $963.50 | $963.79 | $963.79 | 304,400 |
Analyst Price Targets
Based on 11 analysts covering ARGX · as of Oct 5, 2026
Wall Street analysts forecast ARGX stock price to rise 29.3% over the next 12 months.
Consensus
Buy4.45 / 5.00
Avg. Target
US$1180.26
+29.3% Upside
Previously US$1180.17 on Oct 1, 2026
Current Price
US$912.87
Last close
Analyst Breakdown (11 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ARGX's historical volatility
30-Day Vol
25.3%
Annualized
90-Day Vol
43.3%
Annualized
Trend (90d)
+16.5%
Annualized drift
90d Mean
US$968.42
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$931.02 | US$853.27 – US$1015.86 |
| 60 trading days | US$949.54 | US$839.36 – US$1074.17 |
| 90 trading days | US$968.42 | US$832.65 – US$1126.32 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Financials
- Revenue (TTM)
- $5.32B
- EBITDA
- $1.61B
- Profit Margin
- 32.27%
- ROE (TTM)
- 23.64%
- EPS (Diluted)
- 26.29
- Book Value
- 5.38
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ARGX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| GUTS | Fractyl Health, Inc. Common Stock | $4.56 | +1020.39% |
| CMND | Clearmind Medicine Inc. Common Shares | $6.00 | +739.16% |
| AMPGZ | Amplitech Group, Inc. Series B Right | $0.24 | +74.48% |
| VEEA | Veea Inc. | $5.72 | +71.77% |
| PDSB | PDS Biotechnology Corp | $1.20 | +60.21% |
| BEAT | Heartbeam Inc | $0.65 | +50.39% |
| RITRF | Reitar Logtech Holdings Limited | $0.01 | +42.86% |
| QTEX | QTREX Quantum Ltd. | $1.54 | +40.00% |
ARGX.US news timeline
1 article covering ARGX.US, most recent first
Latest